KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Short term Debt (2016 - 2024)

Historic Short term Debt for Gsk (GSK) over the last 9 years, with Q4 2024 value amounting to $3.0 billion.

  • Gsk's Short term Debt fell 1364.55% to $3.0 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $3.0 billion, marking a year-over-year decrease of 1364.55%. This contributed to the annual value of $3.0 billion for FY2024, which is 1418.19% down from last year.
  • Gsk's Short term Debt amounted to $3.0 billion in Q4 2024, which was down 1364.55% from $3.5 billion recorded in Q4 2023.
  • In the past 5 years, Gsk's Short term Debt registered a high of $4.9 billion during Q4 2020, and its lowest value of $3.0 billion during Q4 2024.
  • Over the past 5 years, Gsk's median Short term Debt value was $4.6 billion (recorded in 2022), while the average stood at $4.2 billion.
  • In the last 5 years, Gsk's Short term Debt plummeted by 4470.07% in 2020 and then tumbled by 131.12% in 2021.
  • Gsk's Short term Debt (Quarter) stood at $4.9 billion in 2020, then fell by 1.31% to $4.9 billion in 2021, then dropped by 4.51% to $4.6 billion in 2022, then fell by 24.68% to $3.5 billion in 2023, then dropped by 13.65% to $3.0 billion in 2024.
  • Its Short term Debt was $3.0 billion in Q4 2024, compared to $3.5 billion in Q4 2023 and $4.6 billion in Q4 2022.